Result of AGM

RNS Number : 2150H

Syncona Limited

30 July 2019

 

Syncona Limited

Result of Annual General Meeting 

30 July 2019

At the Annual General Meeting of the Company held today, all Resolutions as set out in the 'Notice of the 2019 Annual General Meeting' dated 27 June 2019 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 13 were proposed as ordinary resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No	Resolution	For	Against	Abstain	Discretion
1	Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2019, together with the Reports of the Directors and Auditors thereon	435,492,895	247,369	0	25,774
2	Re-appointment Deloitte LLP (Guernsey Branch) as Auditors	435,511,635	24,433	214,970	15,000
3	Authorise the Directors to determine the remuneration of the Auditors	435,733,447	4,076	2,742	25,774
4	Re-elect Jeremy Tigue as a Director	421,376,075	12,076,117	2,288,072	25,774
5	Elect Melanie Gee as a Director	435,735,679	0	4,586	25,774
6	Re-elect Thomas Henderson as a Director	435,554,836	183,585	1,844	25,774
7	Re-elect Rob Hutchinson as a Director	435,726,044	9,635	4,586	25,774
8	Re-elect Nigel Keen as a Director	435,304,724	430,954	4,586	25,774
9	Re-elect Nick Moss as a Director	435,734,955	724	4,586	25,774
10	Re-elect Gian Piero Reverberi as a Director	435,735,679	0	4,586	25,774
11	Re-elect Ellen Strahlman as a Director	435,735,679	0	4,586	25,774
12	Approve the directors' remuneration report.	435,688,593	49,828	1,844	25,774
13	Authority to allot shares	435,723,353	12,326	4,586	25,774
14	Authorise the Company to purchase its own shares	435,722,250	12,693	2,742	28,354
15	Disapply pre-emption rights	435,720,338	1,987	4,586	39,128

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.

The full text of the resolutions can be found in the Notice, which is available on the Company's website at www.synconaltd.com/investors.

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: [phone]

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

END

 

 

RAGWGUPAMUPBGUU